Reported 1 day ago
Citi analyst Geoff Meacham has reaffirmed a Buy rating for Eli Lilly and Company (NYSE:LLY), maintaining a price target of $1,190. The positive outlook is bolstered by the company's obesity treatment, tirzepatide, which received the highest cost-effectiveness rating from ICER, indicating its effectiveness compared to lifestyle changes. This favorable evaluation is expected to enhance payer coverage and facilitate access to the drug, highlighting Eli Lilly's solid position in the pharmaceutical market.
Source: YAHOO